A Study of RBI-4000 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

89 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-01

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of RBI-4000 administered at various dose levels via intramuscular injection and to determine the lowest dose of RBI-4000 necessary to elicit the rabies virus neutralizing antibody titer of equal or greater than (\>=) 0.5 international unit per milliliter (IU/mL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

NCT06548139

Rabies Virus Infection

NOT_YET_RECRUITING PHASE2

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

NCT05832073

Rabies Virus Infection

UNKNOWN EARLY_PHASE1

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

NCT04062669

Virus Diseases

COMPLETED PHASE1

Purified Rabies Vaccine for Human Use (Chick-embryo Cell)

NCT00345319

Rabies Post-exposure Prophylaxis

COMPLETED PHASE3

Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

NCT02238756

Rabies

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple Ascending Dose (MAD) Cohorts, Cohort 1: RBI-4000 0.1 mcg

Participants will receive RBI-4000 0.1 micrograms (mcg) via intramuscular injection, once on Day 1 and Day 57.

Group Type EXPERIMENTAL

RBI-4000

Intervention Type BIOLOGICAL

RBI-4000 intramuscular injection.

MAD Cohorts, Cohort 2: RBI-4000 1 mcg

Participants will receive RBI-4000 1 mcg via intramuscular injection, once on Day 1 and Day 57.

Group Type EXPERIMENTAL

RBI-4000

Intervention Type BIOLOGICAL

RBI-4000 intramuscular injection.

MAD Cohorts, Cohort 3: RBI-4000 10 mcg

Participants will receive RBI-4000 10 mcg via intramuscular injection, single dose on Day 1.

Group Type EXPERIMENTAL

RBI-4000

Intervention Type BIOLOGICAL

RBI-4000 intramuscular injection.

MAD Cohorts, Cohort 4: RBI-4000 10 mcg

Participants will receive RBI-4000 ,10 mcg via intramuscular injection, once on Day 1 and Day 57.

Group Type EXPERIMENTAL

RBI-4000

Intervention Type BIOLOGICAL

RBI-4000 intramuscular injection.

Cohort 5: RabAvert 1 mL

Participants will receive RabAvert 1 milliliter (mL), intramuscular injection, once on Day 1 and Day 8.

Group Type ACTIVE_COMPARATOR

RabAvert

Intervention Type BIOLOGICAL

RabAvert intramuscular injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RBI-4000

RBI-4000 intramuscular injection.

Intervention Type BIOLOGICAL

RabAvert

RabAvert intramuscular injection.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Any gender participants between 18 and 45 years old, inclusive, at the time of the first vaccination.
2. Body Mass Index \>18 kilogram per square meter (Kg/m\^2) and less than (\<) 32 Kg/m\^2.
3. Hematological/biochemical values within these parameters:

1. White Blood Cells and differential, within the study designated laboratory normal range.
2. Platelets = 125,000 - 500,000 cells per cubic millimeter (cells/mm\^3)
3. Hemoglobin within normal range of the study designated laboratory
4. Liver function tests including alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase within the study designated laboratory normal range.
4. Female participants of non-childbearing potential or male participants with partners of childbearing potential may be enrolled in the study.
5. Female participants of childbearing potential may be enrolled in the study, if the participant

1. has practiced adequate contraception for 30 days prior to vaccination, and
2. has a negative pregnancy test on the day of vaccination (for female participants),
3. has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series and agrees to not donate sperm (for male participants).

Exclusion Criteria

1. History of diagnosis with rabies exposure, infection or disease.
2. History of rabies immunization (licensed or investigational) or human rabies immune globulin.
3. Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
4. Family history of congenital or hereditary immunodeficiency.
5. History of or current autoimmune disease.
6. History of any reaction or hypersensitivity likely to be exacerbated by any components of commercially available rabies vaccines.
7. Lymphoproliferative disorder or malignancy within previous 5 years (excluding effectively treated non-melanotic skin cancer, Ductal carcinoma in situ /Lobular carcinoma in situ (DCIS/LCIS).
8. History of Type I hypersensitivity reactions to any beta-lactam antibiotics.
9. Any acute or chronic, clinically significant disease, by history, physical examination, laboratory findings, subject personal report, and/or General Physician information.
10. Any history of myocarditis and/or pericarditis.
11. Administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study vaccine or planned administration during the study period.
12. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs including steroids during the period within 6 months prior to the vaccine dose.
13. Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule.
14. Concomitant or planned administration of antimalarial drugs, including hydroxychloroquine within 30 days of vaccination.
15. Current anti-tuberculosis prophylaxis or therapy.
16. Pregnant or lactating female participant.
17. Female participant planning to become pregnant or planning to discontinue contraceptive precautions.
18. Participants with extensive tattoos covering deltoid region on both the arms that would preclude the assessment of local reactogenicity.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes